Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
CADTH
Record ID 32014000811
English
Authors' recommendations:
The Canadian Drug Expert Committee (CDEC) recommends that lurasidone be listed for the management of the manifestations of schizophrenia if the following clinical criteria are met:
1. Patient has a contraindication to less expensive antipsychotic agents, or
2. Patient has failed a trial of less expensive antipsychotics because of intolerance or lack of response.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/complete/SR0331_complete_Latuda_Dec-24-13.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Lurasidone Hydrochloride
- Schizophrenia
- Isoindoles
- Thiazoles
- Antipsychotic Agents
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.